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Antibodies, obtained from myasthenia gravis patients, with reactivity for an immunodominant region of the nicotinic acetylcholine receptor were 
found to also react with muscle myosin. Since amino acid sequence analyses have previously suggested possible serological relationships between 
AChR and a head region sequence of myosm heavy chain, cross-reactive antibodies were examined for their ability to interfere with ATPase activities 
associated with this region of myosin. Results indicated that AChR-specific antibodies purified from MG patient serum by binding to and elution 
from antigen columns were found to inhabit Ca”-dependent, myosin-ass~lat~ ATPase acttvity; interestin~y, this inhibition appeared to be 
relatively selective in that neither K’(EDTA)-dependent nor Mg”-dependent ATPase activities were sensitive to antibody-mediated interference. 
Acetylcholine receptor antibody; Acetylchohne receptor/myosin cross-reacttvity: ATPase inhibitton; Myosin ATPase: Main immunogenic region 
1. INTRODUCTION 
Serum from myasthenia gravis (MG) patients has 
long been known to contain antibodies that react with 
the junctional muscle receptor for the neurotransmitter, 
acetylcholine [l-3]; it has also been previously observed 
that the same patient serum often also contains reactiv- 
ity to other protein antigens associated with striated 
muscle 14-91. A recent report from this laboratory de- 
scribed antibody cross-reactivities that revealed an un- 
expected serological relationship between the ace- 
tylcholine receptor (AChR) and myosin [lo]. Thus, it 
was shown that whether affinity purification of MG 
plasma was performed using Sepharose coupled with 
myosin or the a61-76 AChR a! subunit peptide, the 
binding activities recovered from the plasma of MG 
patients included highly overlapping antibody popula- 
tions. That is, the majority of anti-myosin antibodies 
and the majority of anti-AChR peptide antibodies were 
one and the same. Although the specificity of these 
antibodies for AChR was dearly directed toward a re- 
gion previously characterized [11.121 as being highly 
immunogenic and frequently involved in antibody re- 
sponses in MG patients (i.e. against the so-called Main 
Immunogenic Region [MIR] of the alpha subunit), ex- 
cept for inferences derived from short stretches of iden- 
tity observed by the examination of amino acid se- 
quence data, the region of the myosin molecule that 
provided the cross-reactive antigenic determinant was 
not clearly defined; however, amino acid sequence com- 
parisons suggested that homologies associated with res- 
idues 101-107 of the myosin heavy chain might be in- 
volved. Since this region lies relatively near to both the 
actin binding site, residues 142-148 [13], as well as the 
ATP binding site, residues 178-185 [14,151, it became of 
interest to examine the ability of AChR-reactive anti- 
bodies to interfere with myosin enzymatic function. 
Reported below are observations indicating that 
AChR-reactive (MIR-specific) antibodies obtained 
from the plasma of myasthenia gravis patients are capa- 
ble of inhibiting myosin-associated ATPase activity. 
Four myosin-associated ATPase activities were exam- 
ined that have been described [l&18] based on the ions 
and other co-factors required for the activation of enzy- 
matic function. First, myosin-mediated cleavage of 
phosphate from ATP associated with F-actin-activated, 
Mg”-dependent ATPase appears to be the most physi- 
ologically relevant activity. However, under controlled 
conditions (such as carefully paying attention to effects 
on the oxidation state of two important sulthydryl 
groups), myosin ATPase activities can also be stimu- 
lated by (1) Mg”+ (in the absence of actin), (2) Ca”, and 
(3) NH4 or K’(EDTA). Even though activation of the 
intrinsic ATPases under these latter circumstances i  of 
unsure physiologica significance, the inhibition study 
presented below exploited the multiple means for acti- 
vating myosin ATPase when bound by particular anti- 
bodies in order to gain some insight into the fine-speci- 
ficity of the binding activity present. 
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2. MATERIALS AND METHODS 
2.1 A TPcase assuys 
Microassays for inhibition of ATPase activity were performed with 
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some modification of published methods [13,19] in triplicate in 96-well 
microtiter plates following the incubation of 1 pug samples of myosin 
with a range of dilutions of affinity-purified anti-AChR peptide or 
anti-myosin antibodies (final volume of 30 ~1); incubations were per- 
formed at 4°C for 2 h. Subsequently, ATP as the disodium salt, was 
added to each sample to a final concentration of 0.5 mM; when 
required, 10 pg of actin was added. The ATPase reactions were initi- 
ated by the addition of 10 ~1 (50 ~1) of one of the following reaction 
buffers: (A) For Ca*‘-dependent ATPase. Tris-HCI (100 mM, pH 7.6) 
Cat& (5 mM), KC1 (660 mM); (B) for K’(EDTA)-dependent ATPase. 
Tris-HCI (100 mM, pH 7.6) KC1 (600 mM), EDTA (5 mM); (C) for 
Mg”-dependent ATPase, imidazole (20 mM, pH 7.0), 2 mM MgC&. 
Incubation times were chosen so that no more than 15% of the ATP 
was hydrolyzed and reaction rates were linear. Reactions were termi- 
nated by the addition of 200 ~1 of Malachite green reagent (see below) 
and the presence of liberated phosphate determined by measuring the 
absorbance of each sample at 630 nm using a Dynatech MR5000 
ELISA reader; concentrations of phosphate were determined by com- 
parison to phosphate standards prepared as 50 ~1 samples, represent- 
ing concentrations of phosphate from 50-150 nM. The Malachite 
green reagent used in this assay was prepared by mixing the following 
stock solutions, respectively, in a 1:1:2:2 ratio: Ammonium mo- 
lybdate, 5.72% (w/v) in 6 N HCl, polyvinyl alcohol, 2.32% (w/v) in 
water, Malachite green, 0.0812% (w/v) in water, glass-distilled, deion- 
ized water. Specific activities of myosin-associated ATPase under the 
three sets of conditions described above were determined as nmol 
phosphate released/mg myosin/min; data were sometimes converted 
to percent of uninhibited control. Negative control values (back- 
ground), determined by the absorbance of samples lackmg myosin, 
were subtracted from experimental values; this background of sponta- 
neously hydrolyzed ATP routinely ranged from 0.5-1.0 nmol. 
3. RESULTS AND DISCUSSION 
Antibody binding was evaluated with regard to its 
effects on the enzymatic (ATPase) activity known to be 
localized in the head region of myosin [20,21]. Fig. 1 
shows the consequences, on the Ca*‘-dependent ATP- 
ase associated with bovine myosin, of adding increasing 
amounts of two different preparations of myosin-reac- 
tive antibodies obtained from an MG patient character- 
ized as a Class V myasthenic (severe generalized neu- 
romuscular dysfunction) [ 10,221. Antibodies present in 
plasma were obtained from this patient either by purifi- 
cation on myosin columns (Fig. 1, upper panel) or on 
a61-76 peptide columns (Fig. 1, lower panel). The rate 
of catalytic ATP hydrolysis was maximally inhibited by 
approximately 4&50%; moreover, the dose-responses 
of these inhibitions were virtually identical with regard 
to the two antibody preparations examined. In contrast 
to Ca’+-activated ATPase activity, intrinsic Mg’+-acti- 
vated and K’( EDTA)-activated ATPase activities ap- 
peared completely resistant to the inhibitory potential 
of both preparations of antibodies. This was also true 
when Mg*+ activation was more effectively performed 
in the presence of F-actin (not shown; see Table I), 
These percent inhibitions were derived from the specific 
activities summarized in Table I. 
In searching for an explanation for the serological, 
and possible pathophysiological, relationships between 
myosin and AChR, we are left with the observation that 
only the ability of each of these proteins to interact with 
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Fig. I. Inhibition of intrinsic ATPase activities of bovine myosin by 
anti-myosin antibodies (upper panel) and anti-MIR peptide antibod- 
ies (lower panel). Each of these antibody preparations was obtained 
by affinity-purification of myasthenia gravis patient plasma on the 
appropriate antigen column; previous studies have demonstrated sub- 
stantial cross-reactivity by these two sets of purified antibodies and 
their likely common B lymphocyte origins [lo]. Results obtained from 
3 individual assessments (each performed on triplicate samples) are 
given as the mean percents of ATPase activities (k S.E.M.) remaining 
after exposure to each antibody as a function of antibody concentra- 
tion. Ca’+-activated ATPase, (o,o); Me-activated ATPase, (0,~); 
K’(EDTA)-activated ATPase, (n,r). Maximum change in specific ac- 
tivities of ATPase in the presence of 2 &ml normal human Ig never 
exceeded 10%. 
Ca’+ appears to weakly link the activities under study 
here. A similar structural region required for the bind- 
ing of Ca*’ may therefore serve as the origin of serolog- 
ical cross-reactivity between AChR and myosin; that is, 
the purpose of the AChR, upon binding of ace- 
tylcholine, is to initiate muscle contraction by the 
translocation of Ca*’ across the muscle membrane. In- 
terference of this AChR function (perhaps associated 
with or influenced by antibody binding to the MIR) 
could clearly impair neuromuscular transmission. 
Therefore, it may be no coincidence that the ATPase 
function of myosin that appears to be most directly, and 
apparently selectively, perturbed by antibody binding in 
this study is that which is dependent on interaction with 
Ca’+. Although the contribution of the Ca*’ ATPase 
with regard to muscle contraction is unclear at this time, 
it is intriguing to consider that it might play an essential 
role in the energy dependent transportation of Ca*’ ions 
across the sarcolemma, analogous to the role played by 
the Ca’+-dependent ATPase associated with ion influxes 
and effluxes across the sarcoplasmic reticulum [23]. 
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Antibody specificityb 
Table I 
Effects of antibody binding on the specific activities of myosin-associated ATPases 
ATPase activity” 
Ca” K”( EDTA) Mg”(actin-) Mg’+(actin’) 
None 373 It 6 443* 3 902 6 317+ 25 
Anti-myosin 198 rt 36 411 ? 59 99 + 27 346 -+ 83 
Anti-AChR (MIR) 193246 420 + 67 137 + 17 303 t 110 
Normal human Ig 349i.51 417f20 N.D.’ N.D. 
’ ATPase activity is shown as specific activity (nmol morganic phosphate releasedfmg myosimmin) activated under the conditions indicated. When 
indicated, actin was present at 200 pg/ml. Each individual 50 ~1 microassay of ATP hydrolysis was performed triplicate on each sample; values 
shown are mean specific activities (+ S.E.M.) obtained from 3 independent assessments. Details are given in Fig. 1. 
“Antibodies tested for their ability to inhibit ATP hydrolysis were either obtained, as indicated, from myasthenia gravis serum by affinity 
purification on columns coupled with myosin or columns coupled with the MIR-containing AChR peptide (d61-76). Resulting effects on ATPase 
activtty are shown in comparison to enzyme activities in the absence of any antib~y (None), or m the presence of the imm~oglobufin fraction 
of human serum obtained from a healthy (non-myasthenic) individual. In all cases, antibody concentrations were 2 &$ml. 
‘Not determined. 
On the other hand, AChR and myosin play very dif- 
ferent functional roles in muscle contraction (i.e. reeep- 
tor and ion channel vs. enzyme and structural element 
of the contractile machinery, respectively), have differ- 
ent cellular locations (i.e. extracellular vs. intracellular), 
and do not have any apparent biochemical/structural 
similarity. Furthermore, the most clearly physiologi- 
cally relevant form of the enzyme, F-actin-activated 
Mg2’ ATPase, appears to be resistant o the inhibitory 
effects of the antibodies tested. Therefore, even if mech- 
anisms existed for getting these myasthenogenic anti- 
bodies to their cross-reactive cytoplasmic myosin target, 
no effects on Me/F-a&in ATPase would be predicted. 
Taking these structural considerations together with the 
ATPase inhibition results makes the explanation for the 
potential importance of anti-AChR antibodies in MG 
patients that can also bind myosin totally unclear at this 
time. However, one must take this observed cross-reac- 
tivity into account when attempting to determine the 
etiology of the production of anti-AChR antibodies in 
MG patients, and particularly, the explanation for the 
immunodominance displayed by the MIR. 
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